A Pilot Study of the Utility of 3D Printed Masks for ALS Subjects
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- Michigan Medicine
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age greater than 18
- Ability to communicate in English
- Diagnosis of ALS
- Subject followed in the ALS Clinic at University of Michigan
- Current use of NIV.
Problematic mask leak defined as one of the following:
A. A clinical complaint of mask leak impeding use of PAP AND PAP use <6 hours per night AND/OR B. Average percentage of the night in large leak on download of >10% (AVAPS)
- At least 1 month of NIV use
Exclusion Criteria:
- Subjects successfully using a commercially available mask without objective or subjective leak with good compliance (average use >6 hours per night)
- Silicone allergy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Device Feasibility
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Custom Mask Interface
Patients use a custom mask interface for one month with an option to use for a year if it performs better than a commercial mask.
|
Subjects enrolled in the study will received a custom designed, 3D printed, non-invasive ventilation mask interface.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Average number of hours the custom NIV mask interface is used per night
Time Frame: 1 month
|
Average number of hours the custom NIV mask interface is used per night
|
1 month
|
|
Leak parameters from device
Time Frame: 1 month
|
Average minutes in large leak or leak measured from the device in liters per minute and averaged over the month
|
1 month
|
|
Tidal volume measurements
Time Frame: 1 month
|
(average measured tidal volume/average set tidal volume)*100%
|
1 month
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Interviews with subjects regarding their experience with the custom mask Qualitative assessment of custom NIV mask efficacy
Time Frame: 1 month
|
Interviews with subjects regarding their experience with the custom mask
|
1 month
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
ALS Depression Inventory-12 (ADI-12)
Time Frame: 1 month
|
Depression Scale.
Scales: For each question, the following is selected: "I fully agree", "I agree", "I don't agree", "I do not agree at all"
|
1 month
|
|
ALS Functional Rating Scale, Revised (ALSFRS-R)
Time Frame: 1 month
|
Functional Rating Scale.
Scales: Customized for each question, but 4 is the maximum and generally means 'normal', and 0 represents significant impairment.
|
1 month
|
|
ALS Specific Quality of Life-20 (ALSSQOL20)
Time Frame: 1 month
|
Quality of Life Scale.
Scales: For each question, 1-10 is selected, where 10 means "extremely" and 0 means "not at all".
|
1 month
|
|
Epworth Sleepiness Scale (ESS)
Time Frame: 1 month
|
Sleepiness Scale.
Scales: 3 means "high chance of dozing", 2 means "moderate chance of dozing", 1 means "slight chance of dozing", and 0 means "would never doze".
|
1 month
|
|
PROMIS Neuro-Quality of Life Fatigue Scale
Time Frame: 1 month
|
Fatigue Scale.
Scales: For each question, "Always" (5), "Often" (4), "Sometimes" (3), "Rarely" (2), and "Never" (1) is selected.
|
1 month
|
|
PROMIS Neuro-Quality of Life Sleep Disturbance Scale
Time Frame: 1 month
|
Sleep Disturbance Scale.
Scales: For each question, "Always" (5), "Often" (4), "Sometimes" (3), "Rarely" (2), and "Never" (1) is selected.
|
1 month
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Stephen A Goutman, MD, University of Michigan
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- HUM00112433
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.